FDA 483 - Glenmark Pharmaceuticals Limited - March 15, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Glenmark Pharmaceuticals Limited in Colvale Bardez, Goa, revealed significant deficiencies in their non-sterile drug manufacturing operations. The firm was cited for inadequate equipment cleaning, repeated failures in out-of-specification (OOS) investigations, and a lack of proper quality control unit oversight. Further issues included scientifically unsound sampling plans and an unreliable stability program, indicating systemic problems with quality assurance and product release.
ID · 61572250-35a3-4c58-8beb-ef4ed0be77a2